We can’t show the full text here under this license. Use the link below to read it at the source.
Diagnostic Performance of Eight Blood-based Biomarkers in a Well-characterized Korean Cohort of Preclinical Alzheimer’s Disease
Accuracy of Eight Blood Tests for Early Alzheimer's Signs in a Korean Group
AI simplified
Abstract
Plasma levels predicted with an area under the ROC curve (AUC) of 0.887 in participants with mild cognitive impairment (MCI).
- Higher plasma levels of p-tau181, p-tau217, and were observed in participants with MCI compared to those with subjective cognitive decline (SCD).
- Lower plasma levels of Aβ42 and the Aβ42/Aβ40 ratio were found in Aβ PET-positive participants compared to Aβ PET-negative participants.
- Logistic regression analysis indicated that plasma Aβ42 and p-tau217 levels could predict Aβ PET positivity with a high level of accuracy in the cohort.
- Plasma GFAP levels, along with different p-tau isoforms, were effective in distinguishing between MCI and SCD.
- The findings suggest that blood-based biomarkers may be clinically relevant for identifying preclinical Alzheimer's disease.
AI simplified
Key numbers
0.930
AUC for Aβ-positivity prediction
AUC based on logistic regression analysis of the entire cohort.
45 of 80
Aβ PET-positive participants
Total number of participants diagnosed with .
40 of 63
MCI participants Aβ PET-positive
Number of MCI participants who were Aβ PET-positive.